TITLE

RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL OF ORAL ALOE VERA GEL FOR MILD--MODERATELY ACTIVE ULCERATIVE COLITIS

AUTHOR(S)
Langmead, L.; Feakins, R. M.; Goldthorpe, S.; Hott, H.; Tsironi, E.; de Silva, A.; Jewell, D. P.; Rampton, D. S.
PUB. DATE
April 2004
SOURCE
Gut;Apr2004 Supplement 3, Vol. 53, pA30
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The herbal preparation aloe vera has been claimed to have anti-inflammatory effects and, despite a lack of evidence of its therapeutic efficacy, is widely used by patients with inflammatory bowel disease. Oral aloe vera taken for 4 weeks produces a clinical response more often than placebo, it also improves histological disease activity and appears to be safe. These encouro9ing results suggest that further evaluation of the therapeutic potential of aloe vera gel in inflammatory bowel disease is warranted.
ACCESSION #
13218931

 

Related Articles

  • Postoperative Course of Patients with Ulcerative vs. Granulomatous Colitis. Panish, Joel F.; Nevius, Donald B.; Lipman, Max P. // American Journal of Gastroenterology;Sep1968, Vol. 50 Issue 3, p177 

    Presents a study which examined the difference in the postoperative course of patients with ulcerative and granulomatous colitis. Classification of postoperative patient material; Examination of the gross and microscopic pathology of all cases; Types of primary surgical procedures performed and...

  • Psychological aspects of inflammatory bowel disease. Hisamatsu, Tadakazu; Inoue, Nagamu; Yajima, Tomoharu; Izumiya, Motoko; Ichikawa, Hitoshi; Hibi, Toshifumi // Journal of Gastroenterology;Jan2007 Supplement 17, Vol. 42, p34 

    The article presents a study on the psychological aspects of inflammatory bowel disease (IBD). A history of observations suggest that psychological stress contributes to the course of IBD. An overlap of pathophysiology between IBD and irritable bowel syndrome is seen. The role of psychological...

  • RATIONALE FOR CANCER PREVENTION STRATEGIES IN HIGH-RISK ULCERATIVE COLITIS. Campbell, F. C.; Maxwell, R. J. // Surgeon (Edinburgh University Press);Apr2009, Vol. 7 Issue 2, p96 

    Colorectal cancer (CRC) is the most feared long-term complication in patients with ulcerative colitis (UC) and Crohn's colitis. Surveillance by colonoscopy and serial biopsy is conducted to identify patients most likely to benefit from potentially curative surgery. Within this paradigm, patients...

  • Rituximab.  // Reactions Weekly;1/12/2008, Issue 1184, p30 

    The article describes the case of a 58-year-old man who developed an exacerbation of ulcerative colitis during treatment with rituximab salvage therapy. An overview of the clinical history of the patient is presented, as well as a discussion on the physical and laboratory examinations performed...

  • Recent Indications and Methods of Surgery for Inflammatory Bowel Disease. S. Ohki; S. Terashima; K. Sekikawa; S. Takenoshita; M. Gotoh // Current Drug Targets - Inflammation & Allergy;Jun2003, Vol. 2 Issue 2, p113 

    Inflammatory bowel disease, notably ulcerative colitis (UC) or Crohn disease (CD), is basically benign, but sometimes develops into serious or fatal cancer. While the primary therapies are medical, such as pharmacotherapy and dietetic modification, intractable, serious, and cancerous cases can...

  • Ulcerative colitis. Ghosh, Subrata // BMJ: British Medical Journal (International Edition);04/22/2000, Vol. 320 Issue 7242, p1119 

    Provides information on ulcerative colitis. Clinical features and diagnosis; Etiology; Clinical management; Failure of medical management and its indications for surgery.

  • What's new in inflammatory bowel disease in 2008? Baumgart, Daniel C. // World Journal of Gastroenterology;1/21/2008, Vol. 14 Issue 3, p329 

    Ulcerative colitis and Crohn's disease represent the two major forms of inflammatory bowel disease. In this highlight topic series of articles we cover the latest developments in genetics and epidemiology, intestinal physiology, mucosal immunology, mechanisms of epithelial cell injury and...

  • PREVALENCE AND MANAGEMENT OF INFLAMMATORY BOWEL DISEASE: DATA FROM PRIMARY CARE RECORDS, INCLUDING 5-ASA PRESCRIBING AND COMPLIANCE. Stone, M.A.; Mayberry, J.F.; Baker, R.B. // Gut;Apr2003 Supplement 1, Vol. 52, pA68 

    Background: Data from general practice (GP) records in North Tees (Rubin et al, 2000) suggested a higher prevalence of inflammatory bowel disease (IBD) than previous estimates from hospital data. Regular prescribing of 5-aminosalicylic acid (5-ASA) therapy can reduce the risk of colorectal...

  • The Effects of Armillarisin A on Serum IL-1β and IL-4 and in Treating Ulcerative Colitis. Wu, Ping; Guo, Yonggao; Jia, Fangyuan; Wang, Xiuli // Cell Biochemistry & Biophysics;May2015, Vol. 72 Issue 1, p103 

    To study the therapeutic effect of Armillarisin A on patients with ulcerative colitis (UC) and on serum IL-1β and IL-4, sixty patients with UC were randomly divided into three groups: Armillarisin A treatment group (Group I), Armillarisin-combined hormone therapy group (Group II), and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics